PRESS RELEASE
Gedea Biotech today announced that European patent no. 3 691 625 has entered into force, further strengthening Gedea’s intellectual property protection for pHyph in Europe, until 2038.
The patent covers the use of glucono delta-lactone (GDL) for the treatment of bacterial vaginosis and other bacterial infections protecting the current indications for the company’s lead product pHyph and supporting Gedea’s pipeline expansion into pre term birth.
Europe is Gedea’s first planned launch market for pHyph, and the company is currently engaged in discussions with potential partners interested in commercializing the product across European markets. The strengthened European patent protection is considered strategically important in these discussions, supporting long-term market exclusivity and the value proposition for future commercial partners.
Bacterial vaginosis and other vaginal imbalances during pregnancy are associated with an increased risk of preterm birth. A vaginal microbiome dominated by lactobacilli is linked to a higher likelihood of full-term pregnancy. A treatment that can reduce the risk of preterm birth would have the potential to significantly impact obstetric and neonatal care worldwide.
“This European patent further strengthens our intellectual property position as we prepare for the first launch of pHyph in Europe,” says Annette Säfholm, CEO of Gedea Biotech. “Strong patent protection is an important factor in our ongoing discussions with potential commercial partners and supports the long-term value of pHyph as we expand the product’s potential into additional indications within women’s health,” says Annette Säfholm.